Asdis R. Þorðardottir

Reykjavik, Iceland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Journal: Leukemia

Published: April 22, 2026

Psychiatric health of Icelandic adults 40 years or older: A nationwide study of diagnoses, medications, and symptoms.

Psychiatric health of Icelandic adults 40 years or older: A nationwide study of diagnoses, medications, and symptoms.

Journal: PloS one

Published: August 09, 2025

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.

Journal: Leukemia

Published: June 26, 2025

Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.

Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.

Journal: Archives of dermatological research

Published: July 12, 2024

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

Journal: The British journal of dermatology

Published: July 12, 2024

Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.

Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.

Journal: Blood cancer journal

Published: June 20, 2023

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.

Journal: Haematologica

Published: March 22, 2023

Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening.

Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening.

Journal: Nature medicine

Published: March 21, 2023

Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Journal: Blood cancer journal

Published: March 20, 2023

Prevalence of smoldering multiple myeloma based on nationwide screening.

Prevalence of smoldering multiple myeloma based on nationwide screening.

Journal: Nature medicine

Published: July 07, 2022

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Journal: Blood cancer journal

Published: December 09, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026